{"created":"2023-06-20T15:46:09.103408+00:00","id":741,"links":{},"metadata":{"_buckets":{"deposit":"d27ddcd8-b9de-4080-b494-341447b9e959"},"_deposit":{"created_by":4,"id":"741","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"741"},"status":"published"},"_oai":{"id":"oai:uoeh-u.repo.nii.ac.jp:00000741","sets":["13:24:32"]},"author_link":["2416","2410","2413","2417","2415","2411","2414","2412"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-06-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"153","bibliographicPageStart":"149","bibliographicVolumeNumber":"38","bibliographic_titles":[{"bibliographic_title":"産業医科大学雑誌"},{"bibliographic_title":"Journal of UOEH","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Dapagliflozin, a selective inhibitor of sodium glucose co-transporter 2 (SGLT2), is a novel glucose-lowering agent that has pleiotropic actions on blood pressure and lipids. Its glucose-lowering effect is not mediated by insulin. We report a type 2 diabetic patient whose blood pressure pattern improved from non-dipper to dipper after treatment with dapagliflozin. The 60-year-old man was treated with 5 mg/day dapagliflozin, and the effect of treatment on his blood pressure (BP) was evaluated by ambulatory blood pressure monitoring (ABPM) before and at 8 and 14 days after the start of treatment. The 24-h systolic blood pressure/diastolic blood pressure decreased from 131/87 to 127/83 mmHg at day 14, with a particular decrease in nocturnal blood pressure from 123/84 to 116/75 mmHg (nocturnal blood pressure dip increased from 9.6% to 12.8%), changing from a non-dipper to a dipper blood pressure pattern. Dapagliflozin might potentially improve not only the average blood pressure, but also nighttime blood pressure from non-dipper to dipper in type 2 diabetic patients. \nダパグリフロジンは，SGLT2阻害薬（selective inhibitor of sodium glucose co-transporter 2）のひとつであり，インスリンを介さずに血糖値を改善する作用機序を有する新規2型糖尿病治療薬である．その効果は血糖改善のみならず，血圧，脂質などへの多面的な作用がある．今回，2型糖尿病患者にダパグリフロジンを投与し，血圧がnon-dipperからdipperに改善した症例を経験したので報告する．60歳男性の2型糖尿病患者に対し，ダパグリフロジン5 mg/日を投与し，血圧への影響を評価した．血圧は，投与前，投与後8日目，14日目にABPM （24 hour ambulatory blood pressure monitoring） を測定した．24時間血圧は収縮期血圧：systolic blood pressure （SBP）/拡張期血圧：diastolic blood pressure （DBP） 131/87 mmHgから127/83 mmHgに低下した．中でも，夜間血圧は123/84 mmHgから116/75 mmHgに低下した．その結果，夜間血圧下降度は，9.6 %から12.8 %と上昇し，血圧はnon-dipperからdipperとなった．ダパグリフロジンは平均血圧のみならず，夜間血圧を降下させnon-dipperからdipperへ改善する可能性がある． ","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"産業医科大学（産業医科大学学会）"}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"Journal of UOEH　"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.uoeh-u.ac.jp/kouza/journal/intro_e.html","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"産業医科大学雑誌　"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.uoeh-u.ac.jp/kouza/journal/intro_j.html","subitem_relation_type_select":"URI"}}]},"item_10001_select_24":{"attribute_name":"記事区分","attribute_value_mlt":[{"subitem_select_item":"Case Report(s)"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"ISSN　0387-821X(PRINT), ISSN 2187-2864(ONLINE)","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"森 , 博子"},{"creatorName":"モリ, ヒロコ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2410","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岡田 , 洋右"},{"creatorName":"オカダ, ヨウスケ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2411","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"川口 , 真悠子 "},{"creatorName":"カワグチ, マユコ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2412","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"田中, 良哉"},{"creatorName":"タナカ, ヨシヤ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2413","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Mori, Hiroko ","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2414","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okada, Yosuke ","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2415","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kawaguchi, Mayuko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2416","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tanaka, Yoshiya ","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2417","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-07-22"}],"displaytype":"detail","filename":"04-（英文）森 博子.pdf","filesize":[{"value":"2.7 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"S00038204","url":"https://uoeh-u.repo.nii.ac.jp/record/741/files/04-（英文）森 博子.pdf"},"version_id":"67fb02c0-ca1d-4d24-9912-2ff1b582e50c"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"SGLT2阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"ダパグリフロジン","subitem_subject_scheme":"Other"},{"subitem_subject":"24時間自動血圧測定","subitem_subject_scheme":"Other"},{"subitem_subject":"dipper pattern","subitem_subject_scheme":"Other"},{"subitem_subject":"2型糖尿病","subitem_subject_scheme":"Other"},{"subitem_subject":"SGLT2 inhibitors","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"dapagliflozin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"24 hour ABPM","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"dipper pattern","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"type 2 diabetic patient","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"ダパグリフロジンで血圧がnon- dipper型からdipper型に変わった2型糖尿病の1例","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"ダパグリフロジンで血圧がnon- dipper型からdipper型に変わった2型糖尿病の1例"},{"subitem_title":"A Case of Type 2 Diabetes with a Change from a Non-Dipper to a Dipper Blood Pressure Pattern by Dapagliflozin","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"4","path":["32"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-08-03"},"publish_date":"2020-08-03","publish_status":"0","recid":"741","relation_version_is_last":true,"title":["ダパグリフロジンで血圧がnon- dipper型からdipper型に変わった2型糖尿病の1例"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-06-20T15:58:52.279485+00:00"}